Researcher:
Şahin, Özgün Ekin

Profile Picture
ORCID

Job Title

Master Student

First Name

Özgün Ekin

Last Name

Şahin

Name

Name Variants

Şahin, Özgün Ekin

Email Address

Birth Date

Filters

2021 - 20222

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.2f947695-6a89-45f8-85de-644f4dc95e39

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Virulence determinants of colistin-resistant K. pneumoniae high-risk clones
    (Multidisciplinary Digital Publishing Institute (MDPI), 2021) Department of Industrial Engineering; Ergönül, Önder; Gönen, Mehmet; Can, Füsun; Doğan, Özlem; Vatansever, Cansel; Ataç, Nazlı; Albayrak, Özgür; Karahüseyinoğlu, Serçin; Şahin, Özgün Ekin; Kılıçoğlu, Bilge Kaan; Demiray, Atalay; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Undergraduate Student; Researcher; Faculty Member; Master Student; Department of Industrial Engineering; School of Medicine; Graduate School of Health Sciences; College of Engineering; 110398; 237468; 103165; 170418; N/A; N/A; N/A; 110772; N/A; N/A; N/A
    We proposed the hypothesis that high-risk clones of colistin-resistant K. pneumoniae (ColR-Kp) possesses a high number of virulence factors and has enhanced survival capacity against the neutrophil activity. We studied virulence genes of ColR-Kp isolates and neutrophil response in 142 patients with invasive ColR-Kp infections. The ST101 and ST395 ColR-Kp infections had higher 30-day mortality (58%, p = 0.005 and 75%, p = 0.003). The presence of yersiniabactin biosynthesis gene (ybtS) and ferric uptake operon associated gene (kfu) were significantly higher in ST101 (99%, p <= 0.001) and ST395 (94%, p < 0.012). Being in ICU (OR: 7.9; CI: 1.43-55.98; p = 0.024), kfu (OR:27.0; CI: 5.67-179.65; p < 0.001) and ST101 (OR: 17.2; CI: 2.45-350.40; p = 0.01) were found to be predictors of 30-day mortality. Even the neutrophil uptake of kfu+-ybtS+ ColR-Kp was significantly higher than kfu--ybtS- ColR-Kp (phagocytosis rate: 78% vs. 65%, p < 0.001), and the kfu+-ybtS+ ColR-Kp survived more than kfu--ybtS- ColR-Kp (median survival index: 7.90 vs. 4.22; p = 0.001). The kfu+-ybtS+ ColR-Kp stimulated excessive NET formation. Iron uptake systems in high-risk clones of colistin-resistant K. pneumoniae enhance the success of survival against the neutrophil phagocytic defense and stimulate excessive NET formation. The drugs targeted to iron uptake systems would be a promising approach for the treatment of colistin-resistant high-risk clones of K. pneumoniae infections.
  • Thumbnail Image
    PublicationOpen Access
    SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
    (Oxford University Press (OUP), 2022) Ortiz, Alberto; Yau, Kevin; Cherney, David Z. I.; Kalay, Zeynepgül; Şahin, Özgün Ekin; Çöpür, Sidar; Danacı, Senem; Kanbay, Mehmet; Researcher; Faculty Member; Graduate School of Health Sciences; School of Medicine; N/A; N/A; 368625; N/A; 110580
    Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of novel oral anti-hyperglycemic agents which are increasingly used in clinical practice. SGLT-2 inhibitors improve glycemic control and cardiorenal outcomes, promote weight loss, and reduce blood pressure. Randomized controlled trials have demonstrated that SGLT-2 inhibitors reduce proteinuria and delay progression of kidney disease in patients with albuminuria. However, whether SGLT-2 inhibitors have similar benefits in patients with nephrotic-range proteinuria has not been well established. Evidence to date has been limited to case reports, case series and secondary analyses of randomized controlled trials. This is the first comprehensive review on the effectiveness of SGLT-2 inhibitors for the treatment of patients with nephrotic-range albuminuria or proteinuria. Overall findings support a likely beneficial role of SGLT-2 inhibitors in reducing proteinuria and delaying chronic kidney disease progression in patients with nephrotic-range proteinuria. Lay Summary Sodium-glucose cotransporter-2 (SGLT-2) inhibitors might be a promising agent in non-diabetic kidney patients with proteinuria. Lowering proteinuria may help to improve kidney disease patients' outcome by slowing kidney disease progression and decreasing the risk of new cardiovascular events.